The results of a phase 3 trial show cefiderocol is noninferior, but not superior, to currently used standard-of-care antibiotics in patients with gram-negative bloodstream infections, researchers reported today in The Lancet…
Trial finds cefiderocol isn’t superior to standard antibiotics for bloodstream infections
